Frontlight ResearchEarly access
Active, not recruitingNo phase
Evaluation of Flow Diverter Technology Device for Intracranial Aneurysm
Key facts
- Who runs it
- Jacobs institute
- Where
- Buffalo, United StatesSee the site
- Trial code
- Status
- Active, not recruiting
- People taking part
- 10 people enrolled
- Started
- 1 Sept 2023
- Expected to end
- 30 Dec 2026
- Type of study
- Interventional
- Treatments tested
- Pipeline™ Flex Embolization Device with Shield Technology™
- Record updated
- 10 March 2026
Who can take part
- Age
- 22 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Adults (22 years of age or older) with large or giant wide-necked intracranial aneurysms (IAs) in the internal carotid artery from the petrous to the superior hypophyseal segments
Who cannot take part
- Cannot provide consent or legally authorized representative not available to provide consent
Where in United States
- University at Buffalo NeurosurgeryBuffalo, United States
About the trial
What the trial wants to find out
The Jacobs Institute is participating in a study designed to collect prospective clinical evidence to evaluate the approved use of the Pipeline™ Flex Embolization Device with Shield Technology™ for the endovascular treatment of adults (22 years of age or older) with wide-necked intracranial aneurysms
The group in the trial
- Single arm studyTreatment being tested
Occurrence of thromboembolic event(s)
Treatment: Pipeline™ Flex Embolization Device with Shield Technology™
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 10 March 2026